US 12,391,721 B2
Crystal forms of beta-nicotinamide mononucleotide
David J. Livingston, Worcester, MA (US); Andrew Carr, Hinxton (GB); and Philippe Fernandes, Turnhout (BE)
Assigned to Metro International Biotech, LLC, Worcester, MA (US)
Filed by Metro International Biotech, LLC, Worcester, MA (US)
Filed on Jan. 16, 2025, as Appl. No. 19/025,101.
Application 19/025,101 is a continuation of application No. 18/680,133, filed on May 31, 2024, abandoned.
Application 18/680,133 is a continuation of application No. 17/342,694, filed on Jun. 9, 2021, abandoned.
Application 17/342,694 is a continuation of application No. 16/454,457, filed on Jun. 27, 2019, granted, now 11,059,847, issued on Jul. 13, 2021.
Application 16/454,457 is a continuation of application No. 15/765,325, granted, now 10,392,415, issued on Aug. 27, 2019, previously published as PCT/US2016/054776, filed on Sep. 30, 2016.
Claims priority of provisional application 62/236,657, filed on Oct. 2, 2015.
Prior Publication US 2025/0171485 A1, May 29, 2025
Int. Cl. C07H 19/048 (2006.01); A61K 31/7052 (2006.01)
CPC C07H 19/048 (2013.01) [A61K 31/7052 (2013.01); C07B 2200/13 (2013.01)] 15 Claims
 
1. A method of formulating a cosmetic composition for topical application to human skin, said method comprising (a) obtaining an amorphous compound of formula (I):

OG Complex Work Unit Chemistry
or a salt thereof,
and (b) adding said compound to one or more components to form the cosmetic composition,
wherein:
the composition is an ointment, paste, cream, lotion, or gel; and
the composition is free of absorption enhancers.